Anti-Mouse PCSK9 Antibody (mAb1)

Description: Anti-Mouse PCSK9 Antibody (mAb1) [mAb1] (RA10513) is a rat monoclonal antibody detecting PCSK9 in Blocking, ELISA. Suitable for Human, Mouse, and Monkey.
Highlights:
• Multi-Species — Cross-reactive for translational research.
Host species: Rat
Isotype: IgG1, kappa
Species reactivity: Human, Mouse, Monkey
Form: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Concentration: 1 mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Blocking, ELISA
Target: Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: Please contact with the lab for this information.
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha).
Note: For research use only.